D. E. Shaw & Co. Inc. Has $24.46 Million Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

D. E. Shaw & Co. Inc. increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 16.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,110,501 shares of the company’s stock after buying an additional 155,086 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Cellebrite DI were worth $24,464,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CLBT. NewEdge Advisors LLC raised its position in shares of Cellebrite DI by 600.7% during the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock worth $86,000 after purchasing an additional 3,352 shares during the period. R Squared Ltd purchased a new stake in Cellebrite DI in the fourth quarter worth $100,000. Polen Capital Management LLC bought a new position in Cellebrite DI during the fourth quarter worth about $222,000. Victory Capital Management Inc. purchased a new position in shares of Cellebrite DI in the fourth quarter valued at $234,000. Finally, HighTower Advisors LLC bought a new stake in shares of Cellebrite DI during the fourth quarter valued at about $274,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CLBT has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Lake Street Capital boosted their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $23.43.

Cellebrite DI Stock Performance

CLBT stock opened at $19.83 on Monday. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30. The firm has a 50-day simple moving average of $18.92 and a two-hundred day simple moving average of $20.25. The firm has a market cap of $4.75 billion, a price-to-earnings ratio of -14.27, a PEG ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.